Hemispherx Biopharma and the Swiss Department of Defense,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Hemispherx Biopharma and the Swiss Department of Defense, Civil Protection and Sports Expand Their Collaborative Research Agreement to Include the Study of Alferon(R) and Ampligen(R) Against the Ebola Virus

PHILADELPHIA, Sept. 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE: HEB ) (the "Company" or "Hemispherx"), announced that it expanded its Collaborative Research Agreement to test Alferon®, the only multi-species, natural alpha interferon (IFN) commercially approved in the U.S. and Ampligen®, an experimental drug, to be evaluated against the deadly Ebola virus also under the DEA (Data Exchange Agreement) Annex for Medical Preparedness and Bio-Defense Agreement between the Swiss Surgeon General and the US Department of Defense.

The World Health Organization (WHO) has warned that "The Ebola outbreak will affect more than 20,000 people in West Africa and might spread to more countries, indicating a clinical emergency all over the world."

Col. Dr. Sergei Bankoul, M.D., Swiss Armed Forces Logistics, Medical Services Directorate, Head of Medical CBRN Defense of the Armed Forces and Senior Consultant to the Swiss Surgeon General, Major General Andreas Stettbacher, said, "The Ebola outbreak has killed more than 1,000 people and we are very concerned about its further spread. As the WHO has said, the flood of patients indicates the outbreak could be far more severe than numbers show. Given the scientific basis of Ebola's lethality and the potential ability of Alferon and Ampligen to both possibly replenish and restore an Ebola patient's interferon capability, we are eager to commence testing of these two products." Col. Bankoul went on to say that "The Spiez Lab's also intends to use its new and extensive capabilities to evaluate the possibly broad therapeutic potential of Alferon and Ampligen against a wide range of deadly viruses."

Early events in Ebola virus infection influence the patient's ability to develop an effective immune response. The success of Ebola virus replication is dependent on viral inhibition of initial innate immune responses to infection.  Disarming innate immune responses is a common mechanism employed by highly pathogenic human viruses that include the influenza and corona viral families. Ebola counteracts the host innate immune response by blocking the cellular production of Type I IFN.

A key component of innate immune responses is activation of the Toll-like receptors (TLRs). TLR3 activation by dsRNA is an essential response element to viral infection.  Block TLR3 activation and an essential element of the innate immune response is disarmed. Ampligen, Poly I:Poly C 12 U (rintatolimod) was designed as an IFN inducer and has demonstrated antiviral activity in a wide variety of DNA and RNA viruses in pre-clinical testing.  By replenishing an Ebola patient's natural interferon with Alferon and restoring that patient's innate immune response by Ampligen's overcoming the Ebola blocking mechanisms, Ebola virus replication could be potentially significantly reduced.

Tom Equels, Executive Vice Chairman of Hemispherx, said, "We are excited to offer Alferon N and Ampligen as a potential therapeutic for the treatment of Ebola and other lethal viruses for which there is an unmet medical need.  Should these important experiments being conducted at Spiez Lab render positive results, Hemispherx has the potential to provide large quantities of these products from its GMP facility in New Brunswick, New Jersey. Given that other potential treatments cannot be supplied in quantity, Hemispherx hopes to be a major contributor to minimizing the effects of this outbreak."

About Alferon® N

Alferon® N is the only natural source, multi-species alpha interferon currently approved for sale in the U.S. Alferon® N is approved in the U.S. only for the treatment of refractory or recurring external genital warts caused by human papilloma virus in patients 18 years of age or older.

About Ampligen®

Ampligen®, an experimental therapeutic, is a new class of specifically-configured ribonucleic acid (RNA) compounds targeted as potential treatment of diseases with immunologic defects and/or viral causation.

About Spiez Laboratory

Spiez Laboratory is the Swiss Federal Institute for NBC (Nuclear, Biological, Chemical) Protection and is the leading organization in Switzerland charged with the safety and security of the general population against biological, chemical and nuclear threats.  Spiez Lab has fully equipped and staffed laboratories (about 100 people) for both in-vitro and in-vivo (small rodents, being set up) testing of products to prevent or treat potential NBC types of threats.  Biological testing facilities and staff include BSL (Biological Safety Lab) level 3 and 4.  Spiez Laboratory develops and safeguards the necessary basic scientific and technological knowledge for comprehensive NBC protection.  It also provides national and international organizations, the Swiss authorities, and general population with services to prevent, to prepare for and to manage disasters and emergencies.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutics Ampligen® and Alferon® LDO.  Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome.  Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because both Ampligen® and Alferon® LDO are experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®), approved for sale in the U.S. and Argentina. The Company's Alferon® N approval in Argentina includes the use of Alferon N Injection® (under the brand name "Naturaferon") for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.  For more information please visit www.hemispherx.net

Disclosure Notice

Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties.  For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission.  The final results of these efforts and/or any other activities could vary materially from Hemispherx's expectations.  In vitro experiments are not necessarily predictive of clinical outcome and no representations are made that any products described in this release will be ultimately determined safe and effective in the prevention and/or treatment of the Ebola virus.  Moreover, it would take time, testing and funds to obtain approval of any such product and there are no assurances that a commercial approval for treatment of the Ebola virus can be obtained.

Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Words such as "potential," "potentially," "possible," and similar expressions are intended to identify forward-looking statements.  The inclusion of forward-looking statements should not be regarded as a representation by Hemispherx that any of its plans will be achieved.  These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond Hemispherx's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements.  Examples of such risks and uncertainties include those set forth in the Disclosure Notice, above, as well as the risks described in Hemispherx's filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Hemispherx undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise revise or update this release to reflect events or circumstances after the date hereof.

Company/Investor Contact: Charles Jones CJones & Associates Public Relations Office: 888-557-6480 Cell: 305-987-7418 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 59

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 104

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 123

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 116

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 66

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 142

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 47

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 113

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading
Alliance for Women in Media Champions Change in 2026

Updated Category News Views 76

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 100

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading

Top 5 Most Recently Viewed Articles

South32 Secures Key Environmental Approval for Worsley Mine

Updated Category News Views 283

South32's Worsley Mine Project Receives Environmental Approval Perth-based South32 (ASX / LSE / JSE: S32; OTC: SOUHY), an Australian leader in mining and metals, has recently obtained essential state environmental approval for its Worsley Mine Development Project. This significant milestone brings the company a step closer to accessing necessary bauxite resources, vital...

Continue Reading
Tesla's Future Beyond EVs: The Rise of AI, Robotics, and Robotaxis

Updated Category News Views 471

Tesla's Future Beyond EVs: The Rise of AI, Robotics, and Robotaxis Tesla Inc. (NASDAQ:TSLA) is trading near $418.02, showcasing a remarkable market cap of $1.31 trillion and a P/E ratio of 279.5. This impressive valuation not only underscores the innovation premium associated with Tesla but also reflects the intense valuation pressures it faces. The company has...

Continue Reading
Smartkem Showcases Innovative Display Technology at TechBlick

Updated Category News Views 44

Smartkem Set to Exhibit at TechBlick: A Spotlight on Future Electronics Smartkem, Inc. (NASDAQ: SMTK), a leader in transformative display technologies, is gearing up to showcase its innovative offerings at an upcoming global conference centered on electronics. This event, known as TechBlick: The Future of Electronics Reshaped, will take place at the Estrel Berlin Hotel...

Continue Reading
American Rebel Light Beer: Expanding Horizons in Iowa

Updated Category News Views 170

American Rebel Light Beer Expands Distribution in Iowa American Rebel Light to be served at Knoxville Raceway and the Dingus Lounge Nashville, TN — American Rebel Holdings, Inc. (NASDAQ: AREB) proudly announces its strategic expansion into Iowa through a partnership with Mahaska Bottling Company. This important move marks a significant milestone in the Company's broader...

Continue Reading
Boys & Girls Clubs Ignite Hope with Woodlands Impact Center

Updated Category News Views 195

Boys & Girls Clubs of the Northwest Suburbs Renovate New Facility The Woodlands Impact Center is poised to play a vital role in empowering local youth by providing essential services and programs. This facility aims to support 550 students, offering after-school, summer, and daytime activities that will enrich their educational and social experiences. A Transformative...

Continue Reading